Evolus, Inc. (NASDAQ:EOLS) Stock Has Average Target Price of $14.50 According to Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $14.50.

A number of brokerages have issued reports on EOLS. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Tuesday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Evolus in a research report on Friday, September 11th. BTIG Research reaffirmed a “buy” rating and set a $13.00 price objective on shares of Evolus in a research note on Wednesday, June 17th. Finally, Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th.

Evolus Stock Down 1.0%

Shares of EOLS traded down $0.07 during mid-day trading on Tuesday, reaching $7.67. The company had a trading volume of 17,572 shares, compared to its average volume of 999,565. The stock has a market capitalization of $506.93 million, a P/E ratio of -14.77 and a beta of 1.33. Evolus has a 52-week low of $3.86 and a 52-week high of $9.31. The stock has a 50 day moving average of $8.11 and a two-hundred day moving average of $6.68.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total transaction of $950,176.32. Following the sale, the insider owned 499,592 shares in the company, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EOLS. GAMMA Investing LLC increased its holdings in Evolus by 65.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,288 shares of the company’s stock worth $26,000 after acquiring an additional 1,303 shares in the last quarter. Bank of New York Mellon Corp raised its position in Evolus by 3.9% during the first quarter. Bank of New York Mellon Corp now owns 143,164 shares of the company’s stock worth $588,000 after acquiring an additional 5,367 shares during the period. Legal & General Group Plc acquired a new stake in shares of Evolus in the second quarter valued at about $40,000. Quantbot Technologies LP purchased a new position in Evolus in the 2nd quarter valued at about $56,000. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of Evolus in the second quarter valued at approximately $71,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for healthcare providers and consumers. The company’s portfolio is designed to address facial wrinkles, folds and other signs of aging through injectable aesthetic treatments.

Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines in adults. The company markets Jeuveau in the United States and sells the product internationally under the Nuceiva brand in certain markets.

The company has expanded beyond neuromodulators with its Evolysse collection of injectable hyaluronic acid dermal fillers, which is intended to address facial volume loss and wrinkles.